金吾财讯 | 赛诺菲(SNY)周五表示，美国食品和药物管理局(FDA)已批准Dupixent（又名 dupilumab），用于治疗成人大疱性类天疱疮（BP）患者，这是一种罕见的慢性皮肤病。
此次批准基于2/3期Adept研究的数据，该研究评估了Dupixent与安慰剂相比的疗效和安全性。研究中，18.3%的患者获得了持续的疾病缓解，38.3%的患者获得了临床意义上的瘙痒减轻，而安慰剂组分别为6.1%和10.5%。这家法国生物制药公司还向其他市场申请了Dupixent的监管批准，包括欧盟、日本和中国。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.